In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback